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Abstract
Background: Differences in cancer survival are shaped by differences in health system capacity in workforce and 
infrastructure. Part of the International Cancer Benchmarking Partnership (ICBP), this study explored stakeholders’ 
perceptions of the role of health system capacity necessary for cancer care in influencing cancer survival in 7 high-
income countries.
Methods: We conducted semi-structured interviews with 79 key informants from national, regional, and local tiers 
of health systems, professional bodies, patient associations, and academic experts in Australia, Canada, Denmark, 
Ireland, New Zealand, Norway, and the United Kingdom. Data collection was guided by a conceptual model linking 
characteristics of health systems and cancer survival along the cancer patient journey, from recognition of symptoms at 
pre-diagnostic stages through to survivorship or death. Data were analysed using a thematic approach. 
Results: We identified 3 themes as important in shaping cancer outcomes: primary care and access to diagnostic 
evaluation, specialist care and access to treatment, and workforce pertaining to diagnostic and treatment phases. 
Improved infrastructure for diagnosis and treatment had improved cancer outcomes in all jurisdictions. However, this 
was seen as insufficient if staffing was inadequate. Consolidation of services and greater surgical specialisation was 
important in some jurisdictions if accompanied by a reconfiguration of services, in particular the creation of specialist 
multidisciplinary teams, along with supporting capacity in the wider health system. Staff shortages were commonly cited 
as reasons why some jurisdictions lagged behind others.
Conclusion: Continued improvement in cancer outcomes will require sustained investment in plans to deliver and 
maintain the workforce engaged in cancer care and in the infrastructure on which they depend. However, strategic plans 
must recognise that systems for cancer care do not work in isolation from the rest of the health system and a whole 
systems approach is essential if we are to improve outcomes for an ageing, increasingly multimorbid population.
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Background 
Cancer survival is widely used as an indicator of the quality of 
health systems, with differences in survival between countries, 
and regions within countries, attributed to differences in the 
relative effectiveness of healthcare.1-6 Increasingly, research 
has sought to understand how specific health system features 
may be linked to cancer outcomes and explain the widespread 
variation in survival. Health system features have thus far 
mostly been considered under broad headings, such as 
spending on cancer care or healthcare in general,7,8 focused 
on sub-systems, such as the role of primary care in providing 
access to timely diagnosis,9-12 or investigated specific 
indicators of access, for example, to cancer drugs,10,13-15 or a 
combination thereof. 
Yet, all of these features are part of the wider health 
system, which depends on a range of inputs to function, 
such as health workers and physical capital (facilities and 
equipment). Although the performance of health systems 
ultimately depends on “the knowledge, skills and motivation 
of the people responsible for delivering services”16 [p. 77] the 
health workforce cannot deliver services effectively without 
the necessary infrastructure. In the cancer field, published 
evidence has tended to focus on the strength of individual 
specialties, such as medical or clinical oncology,17-21 and, 
more recently, the workload of medical oncologists,22,23 or 
the availability of equipment, for example, radiotherapy.24 
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Implications for policy makers
• International variation in cancer survival is widely attributed to differences in the relative effectiveness of healthcare but it remains unclear what 
health system features shape cancer care in a way that can improve outcomes. 
• This study highlights the complexity of factors that contribute to observed improvements in cancer survival across countries and over 
time. Although the relative importance of different factors varies across settings, we find that investment in resources, in the form of staff, 
infrastructure, and equipment for diagnosis and treatment, and processes, in particular service consolidation and surgical specialisation, are 
linked to improved quality of care. 
• Continued improvement in cancer outcomes will require sustained strategic investment in plans to deliver and maintain the workforce engaged 
in cancer care and in the infrastructure on which they depend. 
• Strategic plans must recognise that systems for cancer care do not work in isolation from the rest of the health system and a whole systems 
approach is essential if we are to improve outcomes for an ageing, increasingly multimorbid population.
Implications for the public
Countries worldwide are investing resources to make it more likely that people with cancer will be diagnosed early, access timely treatment, and 
increase their chances of surviving. Yet they vary in their degree of commitment, as do cancer survival rates among their populations. Even countries 
that have otherwise similar health systems differ in the way they have built and sustained the ability to deliver effective cancer care. Investments are 
often short term or narrowly focused, for example on equipment for diagnosis or treatment, without the staff needed to operate them. Our research 
stresses the importance of investing in the entire range of components of an effective service for patients with cancer.
Key Messages 
These studies provide important insights into the capacity 
of cancer care systems, but, to our knowledge, only a small 
number of studies, such as those undertaken by the Örenäs 
Research Group,25,26 have examined the role of the workforce 
and physical infrastructure, and their interdependencies, in 
shaping cancer outcomes. This study contributes to filling this 
gap.
The analyses presented in this paper are part of a wider 
study situated within phase 2 of the International Cancer 
Benchmarking Partnership (ICBP-2), a network of policy-
makers, academics and clinicians researching factors 
contributing to differential cancer outcomes among 
countries.27 ICBP-2 includes 7 countries: Australia, Canada, 
Denmark, Ireland, New Zealand, Norway and the United 
Kingdom, chosen because they all have high-quality 
population-based cancer registries, provide universal access 
to healthcare funded primarily from general taxation, and 
spend comparable shares of national income on health.6
Throughout this paper, we use the umbrella term ‘capacity,’ 
broadly defined as the structures, processes and management 
systems that enable organisations and systems to function 
effectively.28 It includes human, physical, and knowledge 
resources and the processes used to transform these resources 
into services or processes. We focus on 2 core resources, 
namely workforce and infrastructure (facilities, equipment), 
examining their perceived role and their interdependencies 
along the cancer care journey, and how those involved in 
cancer care and policy believe that they influence differences 
in cancer outcomes among countries and over time.
Methods
We employed a descriptive qualitative research design,29 
adopting an implicitly positivist approach, using interview 
accounts to understand what key stakeholders understood to 
have been the key policies, strategies or actions that helped (or 
hindered) improvements in cancer survival. Specifically, we 
conducted semi-structured interviews with key informants 
in a subset of the 21 jurisdictions included in ICBP-2. These 
were 2 of 3 Australian states and 3 of 10 Canadian provinces, 
along with Denmark, Ireland, Norway, New Zealand, and the 
4 countries of the United Kingdom (n = 13 jurisdictions). The 
subset was chosen to represent a spread of size of jurisdictions 
and cancer survival estimates while keeping the number of 
interviews manageable within the limited time frame of 
the study. For Canada, we selected Ontario (most populous 
province,30 higher than average cancer survival for Canada2), 
Manitoba (mainly rural, average survival), and Nova Scotia 
(maritime; lower than average survival). For Australia, we 
selected New South Wales (high population density,31 lower 
than average survival for Australia) and Western Australia 
(low population density, higher than average survival). Our 
approach to the study was guided by a conceptual model that 
visualises the range of possible interrelationships and causal 
pathways linking health system factors and cancer survival 
along the cancer care journey, from recognition of symptoms 
at pre-diagnostic stages through to survivorship or death. 
We have described the model in detail elsewhere.32 In brief, 
it provides a first step in the identification of key factors that 
might be amenable to system-level interventions to enhance 
cancer outcomes internationally. It also served to focus our 
qualitative enquiry.
Participant Recruitment
We sought to interview decision-makers at the different tiers 
of the system: hospital managers, regional authorities where 
relevant, and government officials (including arms’ length 
bodies), representatives of professional bodies and of patient 
associations, and other relevant agencies and bodies, both 
within the cancer field and with wider health policy expertise. 
We sought to recruit sufficient numbers of participants from 
each category of decision-maker to ensure data saturation. 
Key informants were identified through a combination of 
purposive and ‘snowball’ strategies,33,34 working with local 
ICBP-2 collaborators in the first instance as well as conducting 
systematic searches of websites of organisations representing 
the range of stakeholders listed above. Members of the ICBP 
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Programme Board were not considered for interview. Where 
appropriate, we invited further study participants following 
recommendations of initial key informants.
For each jurisdiction we sought representation from across 
the main stakeholder groups. The jurisdictions covered by 
ICBP-2 vary in population size and the way health services, 
and cancer services within them, are organised and governed. 
Hence, the range of experts to be interviewed varied by 
jurisdiction. Furthermore, states in Australia, provinces 
in Canada, and, to a lesser degree, the 4 UK countries, are 
subject to national (UK) or federal (Australia, Canada) 
policies and regulations; we therefore also included national 
level representatives from these countries. Informed by our 
previous work,35,36 we sought to recruit approximately 8 
experts in Australia, 20 experts across the 4 jurisdictions in 
Canada, between 6 and 8 experts each in Denmark, Ireland, 
New Zealand and Norway and approximately 20-22 experts 
across the 4 countries of the United Kingdom. 
Interviews
Potential participants were contacted by email and invited 
to take part in an interview using telephone or the online 
telecommunications applications Skype or Zoom; they were 
provided with a project information sheet with the invitation. 
A maximum of 3 emails were sent before replacing a potential 
participant with an alternate. After agreeing to participate, the 
interview was scheduled and participants were provided with 
the topic guide and consent form.
The topic guide was informed by the conceptual model, 
focusing on the diagnostic and treatment/management 
part of the cancer care journey. Interview topics explored 
stakeholders’ views on and understandings of cancer 
policies and services in their jurisdictions, specifically: likely 
explanations for observed improvements and variations in 
cancer survival; key achievements and (continued) challenges 
in organisation and delivery of cancer services along the 
care journey; and perceived effectiveness of policy levers 
and instruments driving cancer services and policies. To 
inform conversations, the topic guide included an illustration 
of survival trends in each of the 7 countries for the period 
1995-2014 and for 4 cancer sites: oesophagus, rectum, 
pancreas and ovary, selected to represent different levels of 
survival between the countries; the topic guide is shown in 
Supplementary file 1. The selection of cancer sites and choice 
of observation period reflects the focus of ICBP-2. We also 
provided an illustration of the diagnostic and treatment 
part of the cancer care journey to facilitate discussions of 
enablers and barriers in the organisation and delivery of 
cancer services in participants’ jurisdictions (Figure). The 
interview guide was pilot tested with 3 members of the ICBP-
2 programme board (representing 3 different jurisdictions) 
to assess understanding and applicability of the topics to 
different contexts.
Interviews were conducted in English by 3 authors (MA, 
MMo, EN) from January 2019 to March 2020. Although we did 
not specifically exclude non-English speaking participants, 
Figure. The Diagnostic and Treatment/Management Part of the Cancer Care Journey. Abbreviations: SACT, systemic anti-cancer therapy; ICU, intensive care unit; 
MDT, multidisciplinary team. Source: Adapted from Morris et al.32
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all participants were fluent in English. The first 20 interviews 
were conducted in pairs of 2 to ensure consistency across 
interviewers. Six interviews included 2 or more interview 
participants. Interviews were recorded with participants’ 
consent and transcribed verbatim. Two interviews could not 
be recorded, and notes were taken instead.
Analysis
Data analysis followed a thematic approach, using the 
stages of data familiarisation, coding (using NVivo version 
12), and theme refinement. Our approach to analysis was 
largely deductive, guided by the World Health Organization 
(WHO) health systems framework16 and the framework 
developed by Atun et al for the analysis of national cancer 
control programmes.37 Specifically, we used thematic content 
analysis, which involved coding interviews using initial codes 
generated from the interview topic guide and the frameworks 
and developing new codes where data did not fit easily into 
existing categories. Following the coding of each interview, 
codes were collated to generate broader themes. 
Results 
We interviewed a total of 79 key informants in 13 jurisdictions 
(Table). Interviews varied in duration from 35 to 77 minutes, 
with an average of 54 minutes. Data saturation was achieved 
for each theme presented below. 
We identified 3 themes as important in shaping cancer 
outcomes: primary care and access to diagnostic evaluation, 
specialist care and access to treatment, and workforce 
pertaining to diagnostic and treatment phases. We discuss 
each of these in turn. 
It is important to note that the majority of interview 
participants highlighted the complexity of factors involved 
that may have contributed to observed improvements in 
cancer survival over time in all jurisdictions. This was seen 
to be particularly relevant for the cancer sites explored in the 
interviews, for which it was not possible to isolate a single 
factor that would stand out in explaining trends, although 
there was widespread agreement that timely diagnosis was key 
to cancer survival. Some interview participants pointed to the 
interdependencies along the cancer pathway, with disruption 
of one factor impacting on the next, and, ultimately, affecting 
survival, which one participant referred to as “the incremental 
effect of one roadblock on another roadblock on another one, 
on another one, on another one […]” [R79 England]. We 
will come back to these interdependencies, and consequent 
knock-on effects, below.
Primary Care and Access to Diagnostic Evaluation
Better access to timely diagnosis was widely perceived to have 
been an important contributor to observed improvements 
in cancer survival. This was attributed to a combination 
of increased investment in diagnostic imaging in most 
jurisdictions, particularly in the 2000s, both in terms of 
infrastructure and workforce, as well as greater standardisation 
of referral pathways to help reduce wait times for diagnostic 
investigations and, thus, treatment. Expanding diagnostic 
technology was referenced by several key informants from 
Denmark, so that they now have the highest number of PET 
(positron emission tomography) scanners in Organisation for 
Economic Co-operation and Development (OECD) countries 
(at 7.6 per million population in 2018), along with Australia 
(at 3.8 compared with 1.9 in Ireland, 1.4 in Canada, and 1 in 
New Zealand38), an observation that several participants from 
the United Kingdom also commented on (“there is a general 
feeling that [Denmark has] moved faster than we have” [R61 
England]). Investment in other diagnostic equipment was also 
recognised as an important factor in survival improvements 
in other jurisdictions, as for example reported for Scotland:
“[T]hey pour the money into endoscopic services to try and 
improve upper and lower GI [gastro-intestinal] endoscopy 
services, and other things to try and improve the diagnostic 
process and speed up the diagnostic process, so I think these 
are the sort of things that have helped” [R76 Scotland].
However, while diagnostic infrastructure and equipment 
were seen as necessary, increasing availability of such 
services in itself was viewed as insufficient to improve cancer 
diagnosis care. Accompanying measures to enhance skills and 
otherwise develop the workforce were essential, as well as 
greater standardisation of diagnostic pathways. Participants 
Table. Organisations Represented by Interview Participants, by Country
Jurisdiction











Australiab 5 2 1 1 1 1 11
Canadac 8 7 2 1 1 - 19
Denmark 1 1 1 2 1 1 7
Ireland 2 1 1 - 1 1 6
New Zealand 3 - 1 - 1 2 7
Norway 1 2 - - 1 1 5
UKd 7 6 2 3 1 5 24
Total 27 19 8 7 7 11 79
a For example cancer societies, charities, members of task forces or committees; b Australia, Western Australia, New South Wales; c Canada, Manitoba, Ontario, 
Nova Scotia; d England, Northern Ireland, Scotland, Wales.
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from several jurisdictions referred to the introduction of 
guidelines and standards to streamline referral from primary 
care to diagnostic evaluation, such as the urgent referral 
pathways for people with suspected cancer (‘2-week-wait’) in 
England from 1999, or fast track referral within the Danish 
cancer patient pathways in 2008, which had been found to 
reduce diagnostic intervals in those jurisdictions.39,40 Despite 
reducing wait times for those with ‘alarm symptoms,’ several 
participants highlighted the challenges of managing those 
with non-specific symptoms “where it’s a small percentage 
probability for having cancer, then you often wait for too long” 
[R68 Norway].
Ease and Speed of Referral
In 2012, Denmark introduced urgent referral for nonspecific, 
serious symptoms via newly established diagnostic centres, 
and, more recently, so-called no-yes-clinics, in which 
the general practitioner (GP) has direct access to rapid 
investigations.41 Taken together, these developments were 
reported to have changed the approach taken by GPs, 
encouraging them to refer more patients: 
“So, if you have a GP that says that 50% of the patients that I 
sent in the cancer package [CCP] they do have cancer then you 
could argue he is very good in selecting patients, or you could 
argue he is really sending too few. […] And I think everybody 
agrees he’s really sending too few. So, he is missing a lot of cancer 
because he’s not sending enough” [R22 Denmark].
A recent shift in willingness of GPs to refer patients with 
vague symptoms for scans was also noted in Wales, supported 
by guidance by the 2005 National Institute for Health and 
Clinical Excellence42; this was expected to improve outcomes 
over time.
Key to these changes is the ability to refer quickly. Danish 
participants identified the regionalisation of diagnostic 
services, with rapid diagnostic centres to facilitate diagnosis as 
contributing to improved cancer outcomes. Ireland introduced 
rapid access clinics from 2008 (for breast cancer, from 2014 
for lung and prostate43), which respondents associated with 
earlier diagnosis and timeliness in initiating treatment. 
More rapid access to diagnostic testing was also seen as an 
important enabler in Australia, where GPs are empowered 
to order tests directly (rather than through a specialist), 
speeding up provisional diagnoses. Some in Australia cited 
this as contributing to Australia’s good performance in cancer 
outcomes relative to other ICBP countries (“that’s the other 
issue that’s worth mentioning, that is different, is that a person 
who presents with a lump, for example, can go to their GP; their 
GP can actually then have a diagnostic phase, and go through 
that process, confirm the diagnosis of cancer, and then refer 
someone into the tertiary system” [R58 Western Australia]). 
Their views were echoed by participants in New Zealand, who 
contrasted the Australian initiative with their experience of 
patients seeking private diagnostic testing there in order to 
circumvent delays at home. 
The ability to refer quickly (or to refer at all) is crucial 
and many jurisdictions reported how, despite improvements 
in diagnostic capacity over time, important challenges 
remained. One was rising demand for imaging, both cancer 
and non-cancer-related, with diagnostic services struggling to 
keep up. This was reported to be particularly problematic in 
those jurisdictions that historically had a lower capacity for 
diagnostic imaging, such as New Zealand (“that whole system 
[complex imaging] is grossly overloaded” [R30 New Zealand]), 
several provinces in Canada, and the 4 UK countries. 
Smaller jurisdictions found this especially challenging with, 
for example, 1 respondent from Canada reporting that while 
there is an expectation of one PET scanner for every 500 000 
people, their province had only 1 for a population of 1.3 
million, which “basically means we’re always one little blown 
fuse away from not having a PET scanner” [R15 Manitoba]. 
Respondents from Wales and Northern Ireland noted similar 
difficulties, with the latter highlighting the need to send 
patients to the Republic of Ireland or to England to access 
PET scans. Irish, Canadian and New Zealand participants 
commented that lack of scanning equipment had restricted 
scans to urgent or sicker patients. As a result, patients whose 
cancers presented with vague symptoms risked delay in 
diagnosis, something an Irish key informant linked to their 
poor survival with ovarian cancer. 
Diagnostic Infrastructure
Lack of strategic investment was cited by several respondents 
in UK countries (“[F]unny thing that the NHS [National Health 
Service] is 70 years old and has never had a diagnostic strategy, 
and diagnosis […] is rather an important part of healthcare” 
[R61 England]), with recognition that the United Kingdom 
was “right at the bottom of the OECD country access rates 
to MRI and CT scanning” [R62 England]. Access to capital 
funding was seen to be crucial in several jurisdictions, adding 
to the challenge of maintaining existing and replacing dated 
infrastructure, which was noted as a continuing challenge in 
Ireland and England especially: 
“So, really you have a backlog of infrastructural needs and 
that extends from the building to the equipment. Now Ireland 
already had quite an ageing capital stock coming into the 
[financial crisis of 2007/08] so we hadn’t really done much on 
capital investment” [R16 Ireland].
Clearly, it is important to have adequate diagnostic 
infrastructure but also the staff to operate equipment, an issue 
raised as a problem in many jurisdictions, especially among 
key informants based in Canada, Ireland, New Zealand, and 
the 4 UK nations, but also recognised as posing increasing 
difficulty in Denmark. Thus, even where equipment was 
available, shortages of key workers to operate scanners 
and interpret results limited access to diagnostic imaging. 
Shortages especially affected radiologists, endoscopists, and 
pathologists:
“So I think it’s pretty clear that diagnostic interval is a real 
concern and that’s largely down to workforce rather than 
necessarily equipment in Scotland. And that’s a problem 
that’s just been slowly getting worse over the years. […] the 
problem is, we don’t know the exact nature of those gaps and 
where they are” [R66 Scotland]. 
While these factors in themselves were widely viewed 
as compromising the diagnostic pathway, and ultimately 
affecting cancer outcomes, several key informants highlighted 
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how blocks at one point in the diagnostic pathway had knock-
on effects. Thus, respondents from both England and Wales 
reflected on the impacts that pressures on hospital capacity 
had on the ability of GPs to refer patients to these services, 
noting that they would be less likely to send their patients 
for a scan because they would not expect these to be carried 
out: “unless we get a change of mindset there, and a change 
of improving capacity and putting the budget in for that, I’m 
not sure we will ever get to where Denmark and Australia are 
heading to” [R61 England].
Specialist Care and Access to Treatment 
There was general agreement among key informants across 
all jurisdictions that the treatment part of the cancer care 
journey had made important contributions to observed 
improvements, in some cases perhaps more so than 
improvements in diagnostics (“once you actually get diagnosed, 
we are much more organised. We’ve got clear pathways, we’ve 
got the multidisciplinary working, all those things, follow-up 
pathways, guidelines, you name it, coming out of our ears” [R77 
Scotland]).
Service consolidation and increased surgical specialisation 
were identified as crucial, especially for the cancer sites 
explored in interviews. Respondents from most jurisdictions 
commented on the important role that concentration of 
surgery for ovarian cancer in a smaller number of specialised 
centres had played in improving survival over the past 2 
decades. Several key informants cited evidence of substantial 
reductions in numbers of facilities, with one respondent from 
Denmark noting how 50 hospital departments performing 
surgery in the late 1990s had fallen to 4 at the time of the 
interview. In Scotland, the ‘CRAG Report’ (Clinical Resource 
and Audit Group) on the management of ovarian cancer 
(1998)44 had led to the creation of managed cancer networks 
and the consolidation of surgery for ovarian cancer (“within 5 
years, instead of having something like 45 or 50 gynaecologists 
operating on ovarian cancer in Scotland, we essentially brought 
it down to a core of about 10 or 12” [R76 Scotland]). 
Centralisation of surgery was linked to subspecialisation 
of surgeons, which some participants viewed as having 
contributed to improved outcomes. For instance, a respondent 
from Ireland who had worked in Ontario commented on how 
centralisation of care in the former had allowed surgeons to 
concentrate their scope of work (with thoracic/upper bowel 
surgeons operating exclusively on oesophageal cancer, and 
lower bowel surgeons on rectal cancer). They contrasted this 
experience to working in Ireland, where this process had 
moved much more slowly. This was echoed by another Irish 
respondent, who noted that surgical oncology, as a surgical 
subspecialty, was yet to emerge as a specific training stream. 
A respondent from Australia suggested that resistance among 
gynaecologists to embrace gynae-oncologists had delayed 
centralising ovarian cancer surgery, which, they argued, 
might explain why ovarian cancer outcomes “are not where 
they should be compared to other cancers” [R51 Australia].
Wider Service Reconfigurations
While centralisation of surgery was clearly seen as important, 
there was recognition that on its own it was insufficient to 
explain improvements in survival. One key informant from 
Nova Scotia, Canada, noted that even though surgery for 
gynaecological and oesophageal cancer was centralised, 
survival was less than optimal. Participants from several 
jurisdictions highlighted the importance of ensuring 
that centralisation was accompanied by wider service 
reconfigurations, in particular the introduction of specialist 
and multidisciplinary teams (“cancer treatment is a team 
sport” [R10 Ireland]) and the co-location of resources, for 
example in designated cancer centres (eg, Ireland, Northern 
Ireland, Ontario). 
“So, the Cancer and Palliative Care Network did identify 
in the early 2000s a concern about outcomes for people 
with upper GI cancers, where surgery was happening at 
low volume centres, and effectively, worked very hard to 
determine what was a reasonable standard of accreditation 
for a centre to be able to undertake upper GI cancer surgery. 
And in doing so, I think substantially improve the survival 
of that group of patients, because of making sure that they’re 
tertiary hospitals that are well set up in terms of access to 
intensive care, specialised anaesthetics, etc, but also surgeons 
doing those procedures frequently, and with a high level of 
skill” [R58 Western Australia].
In England, respondents acknowledged the key role that 
the 2000 NHS Cancer Plan45 had played, for a range of 
malignancies, especially the supporting Improving Outcomes 
Guidance:46 
“[T]he decision was made […] that centres involving 
surgery should have a population of between 1 and 2 million 
people minimum to deal with oesophageal and gastric 
cancer, and between 2 and 4 million to offer surgery for 
pancreatic cancer. And that’s what happened, and it was not 
rigidly enforced across the United Kingdom, but it broadly 
did occur, and it’s occurred in most places” [R79 England].
These developments were accompanied by significant 
investments in radiotherapy in many jurisdictions, which 
participants identified as contributing to improving cancer 
outcomes. Similar to what we heard about diagnostic 
equipment and infrastructure, Denmark substantially 
increased its capacity: “[A]bout 20 years ago […] we estimated 
the number of accelerators needed to deliver high standard 
cancer treatment. And now Denmark is one of the countries 
in the world with the highest concentration of accelerators” 
[R01 Denmark][1]. Sizable increases in radiotherapy capacity 
were also reported by respondents from Australia, Norway, 
Ontario and Scotland. Key informants from Ireland 
highlighted that protected funding had enabled investment in 
new radiotherapy facilities (“despite through all the financial 
crisis of 2008-2009, there was still a wall around the cancer 
money” [R10 Ireland]), although the financial crisis had 
meant delays in implementing the programme in parts of the 
country43 (“a backlog just to catch up on some of the original 
plans” [R16 Ireland]). As with the challenges reported with 
diagnostic equipment, lack of capital funding was reported to 
have undermined radiotherapy capacity in England and New 
Zealand, (“There’s not enough machines” [R26 New Zealand]). 
Yet, even where the physical infrastructure was in place, 
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challenges to providing optimal treatment were noted (“the 
trouble is, like all these things, you solve one problem and another 
bottleneck pops up as an issue.” [R73 Scotland]). Respondents 
from several jurisdictions highlighted the interconnectedness 
of the cancer and wider health systems (“all this other stuff 
going on”), alongside adequate staffing, which can undermine 
an otherwise ‘reasonably well-balanced’ infrastructure: 
“So, in some tumour sites there are not enough theatre 
lists to meet […] demand but we would have surgeons to 
staff them but in other areas we just don’t have the surgical 
workforce either to deliver the volume. […] So, we have a 
challenging pathway in urology services where we simply 
don’t have enough surgeons to meet the cancer workload but 
equally if we had more surgeons, we wouldn’t have enough 
theatre lists” [R35 Northern Ireland].
Access to intensive care unit (ICU) beds and surgical capacity 
within hospitals were frequently mentioned by respondents. 
They noted that advancements in surgical techniques had 
made it possible to operate on some cancer patients who 
would previously not have been considered for surgery, for 
example due to co-existing conditions, but this had also 
increased the demand for ICU beds. One key informant from 
Denmark pointed to intense competition for these beds, with 
their perceived availability (or lack thereof) being considered 
when deciding on treatment of certain patients. Respondents 
from Ireland and Scotland further pointed to the pressures 
created by an ageing population, with increasing numbers of 
frail older patients occupying ICU beds (and acute care beds 
more widely, as noted by respondents from Ontario), thereby 
‘squeezing’ out patients who need ICU admission following 
planned cancer surgery (“those knock-on effects, they try not 
to cancel cancer patients, but inevitably [they have to]” [R73 
Scotland]). In England, most respondents expressed concerns 
about the pressures on NHS hospitals that had built up 
over recent years, and the lack of spare capacity, which will 
inevitably affect patient outcomes:
“Last year, in the winter bed crisis, [location] ended up 
cancelling […] major cancer surgery, mostly due to lack of 
critical care bed space. But then, that was in the midst of a 
complex flu outbreak and there would always be those sort of 
bottlenecks. […] usually we manage to get it through, but that 
will happen, but having spare capacity – we try and run our 
hospitals and somewhere between 85% and 92% occupancy. 
And we’re never there, we’re always at much higher – 95%, 
96%, some of them 101%” [R65 England].
Pressures such as those described above were not reported 
everywhere, with respondents from Australia and Norway 
viewing surgical capacity, in the form of operating theatres 
and bed numbers, as sufficient.
Workforce Along the Cancer Care Pathway
Staff shortages were commonly cited as preventing countries 
from making as much progress in cancer outcomes as 
elsewhere, with consequences all along the care pathway. 
Respondents attributed these shortages to a range of factors, 
from training insufficient numbers and an ageing workforce, 
with retirement of existing staff, to workforce migration and 
difficulties recruiting and retaining specialists in rural or 
remote settings, although the relative importance of these 
varied within and across jurisdictions. 
A common challenge reported across the board was that 
of meeting the increasing and increasingly complex demand 
for medical oncology services (“the input you need to keep the 
patient on treatment and there aren’t enough bodies to do that. 
There’s not enough bodies to do the demand” [R63 England]). 
This was, as expected, greatest where there were shortages 
of these specialists, as in Wales, but even those jurisdictions 
that had invested heavily in the medical oncology workforce, 
including Australia, Ireland, Manitoba and Norway, reported 
difficulties in keeping up with increasing demand vis-à-vis 
therapeutic advances: 
“The cracks are starting to appear in it because of the 
expense and complexity that’s coming on everywhere now, 
and the expectations and the immunotherapy, and patients 
are no longer dying, they’re living so our clinics are getting 
bigger and bigger and bigger… We’re currently suffering a bit 
of angst with low manpower numbers, and we’re having to 
put patients on waiting lists. We have never done that before” 
[R55 Western Australia].
The Wider Workforce
However, even where the medical oncology workforce was 
considered adequate, specialists depend on other medical 
and nursing staff to provide the multidisciplinary care that, as 
many respondents noted, are needed to deliver high-quality 
care to cancer patients and that, ultimately, will improve 
survival. 
“And that’s the real thing. Now the rate-limiting steps vary 
from one part of the United Kingdom to another. So, in some 
places it’s actually a shortage of nurses to look after patients 
on the ward, in other places it’s the number of nurses that 
you have available in operating theatres. In others its lack of 
intensive care staff, so if you look at, say, nursing shortages, 
you know, in one institution it could be one of those groups, 
in another institution it could be another” [R79 England].
Staff shortages were reported as particularly challenging by 
respondents from smaller jurisdictions and those with large 
rural or remote areas. Here, the main issue was recruitment 
and retention in the context of an increasingly global market. 
For instance, participants from Ireland noted a history of 
health professionals trained there migrating elsewhere, in 
particular following the 2007/2008 financial crisis, with one 
respondent pointing to the impact this had on delivering 
radiation therapy and, thus, cancer outcomes: 
“[W]e’ve had no difficult[y] in attracting high-quality 
trainees, and we train them and most of them leave the 
country and don’t come back. So, we are operating a very 
effective radiology training system for Canada, the United 
States and the UK, and a bit of Australia now as well” [R25 
Ireland].
Within-country competition for nurses and specialists 
was cited as an added challenge for Canada and the United 
Kingdom. For example, respondents from Ontario highlighted 
a shortage of radiotherapy staff, as locally trained physicians 
migrated to other Canadian provinces. Participants in other, 
poorer provinces reported how physicians were moving to 
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wealthier ones. Respondents from Northern Ireland, Scotland 
and Wales pointed to the challenges the wider ‘UK-market’ 
for health professionals posed for them: 
“I mean let’s take a figure, if you take, I don’t know, 5 
physicists in each cancer centre, maybe we’ve got 25 or 30 
physicists across Scotland, if 4 of them leave [for England] 
that’s 20% of our workforce gone. If you’ve got 500 in 
England and 40 leave, it won’t even scratch the surface. So, 
we are more vulnerable to movement of whole people” [R77 
Scotland].
Many countries have long faced major challenges in staffing 
rural and remote communities, with contemporary examples 
reported by participants from Canada, Denmark, Ireland, 
Northern Ireland, Scotland, and Wales. For instance, a Nova 
Scotian participant recounted that a small community in the 
province had managed to obtain a radiotherapy machine, but 
not the staff to operate it (“They just don’t want to go there” 
[R14 Nova Scotia]). Participants from several jurisdictions 
described how regionalisation of services and the use of 
telehealth could overcome some of these challenges, providing 
cancer services closer to people’s homes, but this could not 
overcome all the challenges of attracting and retaining staff.
Discussion 
Main Finding
Study participants from 7 high-income countries shared their 
perspectives of how the capacity of health systems, in the form 
of health workers and physical infrastructure, here facilities 
and equipment, had impacted on the ability to provide timely 
and effective care. Their observations are, in themselves, 
not surprising, and illustrated by, for example, empirical 
evidence of variation in access to cancer diagnosis and 
treatment, although the clinical impact in terms of survival 
outcomes is often not clear.47,48 However, the added insights 
offered by stakeholders interviewed for this study are the 
interdependencies between different parts within the cancer 
system, and the cancer and wider health system within which 
it sits. Many public and political discourses about cancer 
outcomes are dominated by much narrower issues, such as 
access to a new drug that might benefit a handful of patients 
and, even then, for only a short time.49 It is easy to overlook 
the bigger picture, whereby the ability to improve outcomes, 
through faster diagnosis and better treatment, depends on the 
people who provide the care and the tools they have to do so. 
Crucially, this includes resources in the broader health system 
and not just those elements we think of as most intimately 
involved in cancer care.
The 7 countries studied have achieved very different 
survival rates and have progressed at different speeds (see 
Supplementary file 1).2 Yet they all have health systems that 
are, in many respects, comparable. For this reason, they offer 
a rich natural laboratory from which to learn. Patients with 
cancer embark on a journey through different diagnostic and 
treatment processes, navigating a complex health system in 
which there are both barriers to slow them and facilitators to 
speed them on their way.32 Importantly, a barrier at one point 
can have consequences that affect subsequent stages in the 
journey, as clearly highlighted by participants in this study. 
Yet, there are challenges in drawing lessons that can be 
generalised. Health systems are, like all human systems, 
complex and adaptive. A change in one aspect can have 
consequences in others, with both positive and negative 
feedback loops. As interview participants noted, changes in 
service delivery and advances in diagnosis and treatment 
were interlinked. Thus, while centralisation of surgical 
provision was seen widely as good, to achieve all the benefits 
it was necessary to implement wider service reconfigurations, 
including the introduction of multi-disciplinary teams. 
Moreover, specific compensatory mechanisms may be needed 
where facilities serve remote rural areas. 
Comparison With Existing Literature
The importance of context is apparent from the empirical 
literature. At one level, there is evidence to link a broadly-
based programme of reform to improved outcomes, as has, for 
example, been shown for the English national cancer plan.50 
There is also systematic review evidence of improvements 
in survival for certain cancers treated in specialised centres 
compared to those receiving treatment elsewhere, such as 
ovarian and colorectal cancer.51-53 However it is much more 
difficult to directly link service change to cancer outcomes at 
the system level. For example, Varagunam et al studied the 
centralisation of oesophago-gastric cancer services in England 
from the early 2000s.54 This found that the number of NHS 
trusts performing surgical resections more than halved over 
a 10-year period while surgical volume within trusts doubled. 
Postoperative mortality also fell, but only a small part of this 
decline was explained by NHS trust volume. Similarly, a study 
of pancreatic cancer in Denmark reported that surgery had 
been centralised from 12 performing units in 2001 to 4 by 
the mid-2010s. While volume had increased in all 4 units 
over time, 2 of the centres performed about 80%; importantly 
there was no clear relationship between volume and one-year 
mortality post-surgery, although numbers were small.55 
A related concern is the uneven implementation of 
centralisation of cancer surgery across jurisdictions as 
has been noted for ovarian cancer in England.56 Evidence 
from other service areas, such as stroke services,57 
highlights that the implementation of national guidance on 
service reconfiguration including centralisation is rarely 
implemented uniformly across local systems, reflecting local 
capacity, resources and commitment. It was this latter point 
that our interview participants kept returning to, emphasising 
the capacity of the health system to respond, but to do so 
in an integrated fashion. As was noted, there is no point in 
acquiring an expensive scanner if there are no staff to operate 
it. The majority of jurisdictions included in this study have 
invested in physical infrastructure for diagnosis and testing as 
well as in particular groups of health workers, such as medical 
oncologists and radiologists. Yet, the pace of investment has 
frequently not (or only just) caught up with pace of patient 
demand and advances in treatment, an issue that has come 
to the fore in the more recent period in most jurisdictions. 
The only exceptions were Denmark and Norway, and, more 
recently, Australia, but even here rising demand, combined 
with the availability of innovative new treatments, is 
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beginning to outstrip capacity, both in terms of infrastructure 
and workforce. 
Finally, although we focused on discrete jurisdictions, 
several participants emphasised the global nature of 
healthcare, with migration of skilled health workers within 
and between countries posing significant challenges. It seems 
counterintuitive to train people with marketable skills if the 
system fails to provide the incentives necessary to retain them. 
Worldwide, there is a shortage of medical/clinical oncologists, 
many of whom report high clinical volumes, insufficient time 
for continuing professional development, a lack of support 
from other staff, and limited access to newer treatments.22,23,58 
This requires a global solution. 
Strengths and Limitations
While we were able to draw on a wide range of key informants 
in the cancer care and wider health systems fields in the 7 
high-income countries, some jurisdictions and organisations 
were better represented than others (Table), and we might 
lack perspectives where the number of interview participants 
was small. Likewise, interviews were carried out in English 
language only, including in Denmark and Norway. It is possible 
that we missed key informants in these countries who did not 
feel confident speaking English. Nevertheless, we interviewed 
people in senior roles, and we observed that respondents 
from a given jurisdiction were typically in agreement about 
key observations with very few conflicting positions. Thus, 
we feel confident that we have captured key perspectives. 
Importantly, our unit of investigation was the jurisdiction 
but we are aware of within-jurisdiction variation in access to 
cancer diagnosis and treatment or of treatment patterns,47,59,60 
an issue that was commented on by many study participants, 
too. Indeed, variation within jurisdictions may be greater than 
variation between jurisdictions. This highlights the need for 
studies that explore sets of local ‘cancer systems’ in the context 
of the wider health system in order to better understand the 
impacts of differences in diagnostic and treatment patterns 
and their impacts on cancer patient outcomes.
Conclusion
This study highlights the complexity of factors that contribute 
to observed improvements in cancer survival across countries 
and over time. Although the relative importance of different 
factors will vary across settings, it was possible to plausibly 
link investment resources, that is, staff, infrastructure and 
equipment for diagnosis and treatment, and processes, in 
particular service consolidation and surgical specialisation, 
with improved quality of care. It confirms observations from 
elsewhere that have emphasised the importance of primary 
care and timely diagnosis for cancer survival although the 
treatment part of the cancer care journey was equally key to 
observed improvements. Continued improvement in cancer 
outcomes will require sustained strategic investment in plans 
to deliver and maintain the workforce engaged in cancer care 
and in the infrastructure on which they depend. However, 
strategic plans must recognise that systems for cancer care 
do not work in isolation from the rest of the health system 
and a whole systems approach is essential if we are to improve 
outcomes for an ageing, increasingly multimorbid population.
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Endnotes
[1] According to data from the International Atomic Energy Agency, in 2018/2019 
Denmark had 9.1 LINACs per 1 million population compared to 9/1m in Australia, 
8/1m in Ireland, 7.9/1m in Norway, 7.5/1m in Canada, 5.7/1m in New Zealand 
and 5.2/1m in the United Kingdom. However, data are difficult to compare as 
some countries include machines in the private sector (eg, Ireland), while others 
do not (eg, New Zealand).
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